美国儿童耐多药结核病流行病学(1993-2014)
分析1993-2014年美国国家结核病监测系统中新诊断的儿童(<15岁)结核病病例,发现20789例中仅24.8%细菌学确诊,4826例有药敏结果者中82例(1.7%)为耐多药结核病;严格细菌学标准可能低估真实负担,调查的高负担州临床诊断病例低估达42%-55%。
要点
- 儿童结核病细菌学确诊率低(24.8%),仅用药敏确诊会低估耐多药负担。
- 药敏确诊的儿童耐多药结核病占1.7%,多数对至少一种其他一线药耐药。
- 高负担地区临床诊断的耐多药病例可致细菌学标准低估42%-55%。
核心结论
- 仅四分之一儿童结核病病例有细菌学确诊,严格细菌学标准可能低估美国儿童耐多药结核病真实负担。
- 需结合基于流行病学标准的临床诊断来更好地估计儿童耐多药结核病负担。
研究设计与样本
- 分析1993-2014年美国国家结核病监测系统报告的新诊断儿童(<15岁)结核病病例的人口学、临床和实验室数据。
- 耐多药结核病定义为培养确诊且对至少异烟肼和利福平耐药。
- 调查高负担州临床诊断并接受耐多药结核病治疗的病例以评估低估程度。
主要发现
- 20789例儿童结核病中,5162例(24.8%)为细菌学确诊。
- 4826例(93.5%)有药敏试验,其中82例(1.7%)为耐多药结核病。
- 耐多药病例中女性51例(62%),中位年龄5岁(IQR 1-12岁),西班牙裔28例(34%),美国出生55例(67%)。
- 66例(81%)对至少一种其他一线药耐药,73例检测中有24例对至少一种二线药耐药。
- 2013年前开始治疗的77例中,66例(86%)完成治疗,4例(5%)死亡。
关键数值与推荐
- 耐多药结核病定义:培养确诊结核病且对至少异烟肼和利福平耐药。
- 在调查的4个高结核病负担州/辖区,仅用培养确诊定义时儿童耐多药结核病病例低估42%-55%。
临床怎么用
- 临床医生应意识到儿童结核病细菌学确诊率低,仅依赖培养和药敏可能漏诊耐多药病例。
- 在儿童结核病诊疗中应考虑结合流行病学标准进行临床诊断耐多药结核病。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) is an important global public health threat, but accurate estimates of MDR-TB burden among children are lacking. METHODS: We analyzed demographic, clinical, and laboratory data for newly diagnosed pediatric (age <15 years) TB cases reported to the US National TB Surveillance System during 1993-2014. MDR-TB was defined as culture-confirmed TB disease with resistance to at least isoniazid and rifampicin. To ascertain potential underestimation of pediatric MDR-TB, we surveyed high-burden states for clinically diagnosed cases treated for MDR-TB. RESULTS: Of 20789 pediatric TB cases, 5162 (24.8%) had bacteriologically confirmed TB. Among 4826 (93.5%) with drug susceptibility testing, 82 (1.7%) had MDR-TB. Most pediatric MDR-TB cases were female (n = 51 [62%]), median age was 5 years (interquartile range, 1-12 years), one-third were Hispanic (n = 28 [34%]), and two-thirds (n = 55 [67%]) were born in the United States. Most cases had additional resistance to ≥1 other first-line drug (n = 66 [81%]) and one-third had resistance to ≥1 second-line drug (24/73 tested). Of 77 who started treatment prior to 2013, 66 (86%) completed treatment and 4 (5%) died. Among the 4 high-TB-burden states/jurisdictions surveyed, there was 42%-55% underestimation of pediatric MDR-TB cases when using only culture-confirmed case definitions. CONCLUSIONS: Only one-quarter of pediatric TB cases had culture-confirmed TB, likely resulting in underestimation of true pediatric MDR-TB burden in the United States using strictly bacteriologic criteria. Better estimates of pediatric MDR-TB burden in the United States are needed and should include clinical diagnoses based on epidemiologic criteria.
引用
- Smith SE, Pratt R, Trieu L, et al. Epidemiology of Pediatric Multidrug-Resistant Tuberculosis in the United States, 1993-2014. Clin Infect Dis. 2017. PMID: 28633501. doi:10.1093/cid/cix561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。